Європейський Союз - ісландська - EMA (European Medicines Agency)

eli lilly nederland b.v. - mirikizumab - ristilbólga, þvagsýrugigt - Ónæmisbælandi lyf - omvoh is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.

Ісландія - ісландська - LYFJASTOFNUN (Icelandic Medicines Agency)

accord healthcare b.v. - bendamustinum hýdróklóríð - stofn fyrir innrennslisþykkni, lausn - 2,5 mg/ml

Ісландія - ісландська - LYFJASTOFNUN (Icelandic Medicines Agency)

glaxosmithkline pharma a/s - diphtheria toxoid; tetanus toxoid; pertussis toxoid; filamentous haemagglutinin; pertactin; poliovirus inactivated type 1; poliovirus inactivated type 2; poliovirus inactivated type 3 - stungulyf, dreifa - áfyllt sprauta

Європейський Союз - ісландська - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - ceftolozane súlfat, tazobactam járn - bakteríusýkingar - sýklalyf fyrir almenn nota, - zerbaxa is indicated for the treatment of the following infections in adults:complicated intra abdominal infections;acute pyelonephritis;complicated urinary tract infections;hospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap). Íhuga ætti að opinbera leiðsögn á réttri notkun af sýklalyfjum.

Європейський Союз - ісландська - EMA (European Medicines Agency)

ceva-phylaxia veterinary biologicals co. ltd - turkey herpes virus, strain rhvt/nd/ibd, expressing the fusion protein of newcastle disease virus and the vp2 protein of infectious bursal disease virus, live recombinant - Ónæmissjúkdómar fyrir fugla - embryonated chicken eggs; chicken - for the active immunisation of one-day-old chicks or 18-day-old chicken embryonated eggs to reduce mortality, clinical signs and lesions caused by newcastle disease virus (ndv) and to reduce virus shedding; to reduce mortality, clinical signs and bursa lesions caused by very virulent infectious bursal disease virus (ibdv); to reduce mortality, clinical signs and lesions caused by classical marek’s disease virus (mdv).

Ісландія - ісландська - LYFJASTOFNUN (Icelandic Medicines Agency)

glaxosmithkline pharma a/s - lifrarbólgu b yfirborðsmótefnavaki - stungulyf, dreifa

Ісландія - ісландська - LYFJASTOFNUN (Icelandic Medicines Agency)

glaxosmithkline pharma a/s - pertussis toxoid; filamentous haemagglutinin; pertactin; diphtheria toxoid; tetanus toxoid - stungulyf, dreifa - áfyllt sprauta

Ісландія - ісландська - LYFJASTOFNUN (Icelandic Medicines Agency)

glaxosmithkline pharma a/s - varicella-zoster virus - stungulyfsstofn og leysir, lausn - 2.000 pfu bóluefni

Ісландія - ісландська - LYFJASTOFNUN (Icelandic Medicines Agency)

glaxosmithkline pharma a/s - lifrarbólguveira a (deydd) - stungulyf, dreifa - 1440 elisa ein./ml

Європейський Союз - ісландська - EMA (European Medicines Agency)

ceva santé animale - óvirkt coxiella burnetii bóluefni, stofn nine mile - immunologicals for bovidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) - goats; cattle - cattle: , for the active immunisation of cattle to lower the risk for non-infected animals vaccinated when non-pregnant to become shedder (5 times lower probability in comparison with animals receiving a placebo), and to reduce shedding of coxiella burnetii in these animals via milk and vaginal mucus. , onset of immunity: not established. , duration of immunity: 280 days after completion of the primary vaccination course. , goats: , for the active immunisation of goats to reduce abortion caused by coxiella burnetii and to reduce shedding of the organism via milk, vaginal mucus, faeces and placenta. , onset of immunity: not established. , duration of immunity: one year after completion of the primary vaccination course.